Month: October 2021

KISQALI® (ribociclib) tablets

KISQALI® (ribociclib) tablets KISQALI (ribociclib) is a kinase inhibitor. The chemical name of ribociclib succinate is: Butanedioic acid—7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl) pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide (1/1). Ribociclib succinate is a light yellow to yellowish brown crystalline powder. The molecular formula for ribociclib succinate is C23H30N8O·C4H6O4 and the molecular weight is 552.64 g/mol (Free base: 434.55 g/mol). KISQALI film-coated tablets are supplied …

KISQALI® (ribociclib) tablets Read More »

AVSOLA (infliximab-axxq) for injection

AVSOLA (infliximab-axxq) for injection

AVSOLA is a tumor necrosis factor (TNF) blocker indicated for Crohn’s Disease, Pediatric Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis in combination with methotrexate, Ankylosing Spondylitis, Psoriatic Arthritis and Plaque Psoriasi

ERLEADA® (apalutamide) tablets

ERLEADA® (apalutamide) tablets

Apalutamide is an Androgen Receptor (AR) inhibitor that binds directly to the ligand-binding domain of the AR. Apalutamide inhibits AR nuclear translocation, inhibits DNA binding, and impedes AR-mediated transcription.

DESCOVY® (emtricitabine and tenofovir alafenamide) tablets

DESCOVY® (emtricitabine and tenofovir alafenamide) tablets

DESCOVY is a two-drug combination of emtricitabine (FTC) and tenofovir alafenamide (TAF), both HIV nucleoside analog reverse transcriptase inhibitors (NRTIs), and is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg.